Q2 2024 Cytosorbents Corp Earnings Call Transcript
Key Points
- CytoSorbents Corp (CTSO) reported a 10% increase in product sales to $8.8 million for the second quarter of 2024.
- The company achieved a significant reduction in operating loss by 48%, decreasing from $6.6 million in Q2 2023 to $3.4 million in Q2 2024.
- Gross product margins improved to 75% in the second quarter of 2024, indicating enhanced operational efficiencies.
- CytoSorbents Corp (CTSO) secured a $20 million credit facility with Avenue Capital Group, strengthening its financial position.
- The company is on track to submit marketing applications for its DrugSorb-ATR system to the FDA and Health Canada, with potential FDA decision expected within 6 to 12 months post-submission.
- Second quarter 2024 grant revenue decreased to $1.1 million from $1.3 million in 2023 due to the conclusion of several grants.
- The company reduced its workforce by 17% over the past five months, indicating potential challenges in maintaining operational scale.
- Despite improvements, the company still reported an operating loss of $3.4 million for the second quarter of 2024.
- The transition to a new manufacturing facility previously led to a decline in gross margins, although improvements are being realized.
- CytoSorbents Corp (CTSO) is actively pursuing alternative sources of capital, indicating ongoing financial pressures.
Ladies and gentlemen, good afternoon, and welcome to the CytoSorbents Second-Quarter 2024 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the company's request.
At this time, I'd like to turn the call over to our moderator, Eric Ribner. Please go ahead, Mr. Ribner.
Thank you, and good afternoon. Welcome to CytoSorbents second quarter 2024 financial and operating results conference call. Joining me today from the company are Dr. Phil Chan, Chief Executive Officer; Vincent Capponi, President and Chief Operating Officer; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, Chief Medical Officer; Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of CytoSorbents Europe; and Christopher Cramer, Senior Vice President of Business Development.
Before I turn the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
